The patient was 4 years old in 2006 when she arrived at Houston-based Texas Children’s Hospital to receive therapy for nerve-cell cancer that had spread to her bones. She received a first-generation edition of the treatment.
“This provides me with a lot of hope,” Sneha Ramakrishna, MD, a pediatric oncologist and cancer researcher at Stanford (Calif.) University School of Medicine, told Nature. “We’re going to unlock CAR-T cells for people with solid tumors.”
Since 2017, seven CAR-T cell therapies have been approved by the FDA and have shown what the journal called “stunning” results in some blood cancers. Some patients have remained cancer-free for more than a decade following treatment. However, researchers have been unable to repeat success against solid tumors such as neuroblastoma, a nerve-cell cancer.
But with one success story and new iterations of the therapy, researchers are hopeful to change that trend, according to the report.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
